Adverum Biotechnologies Presents Additional Clinical Data From its Phase I Intravitreal Gene Therapy for Wet AMD
Adverum Biotechnologies (NASDAQ: ADVM), a clinical-stage Company focused on developing therapeutics for ocular and rare diseases through gene therapy, released additional clinical data from its ongoing OPTIC phase 1 clinical trial of ADVM-022. ADVM-022, the Company’s lead ocular candidate, is an adeno- associated virus (AAV)....
